Accelerating compliance
and approvals with unmatched regulatory insight and experience.

Contact Us Today
The Lachman Difference

The most efficient services.
The most qualified professionals.

Since 1978, Lachman Consultants’ multidisciplinary team of highly experienced FDA consultants and industry experts has offered compliance, regulatory affairs, and science & technology services to clients around the world.

Learn More About Us

Stay in the know

Sign up today for the Lachman Consultants blog.

Get the latest news on industry compliance, regulatory affairs, technical services, and a whole lot more.

    AREAS SERVED BY LACHMAN CONSULTANTS

    ADVANCE. CONFIDENTLY.

    As long-standing leaders in technical and regulatory consulting services, Lachman Consultants provides both experience and excellence through an unmatched team of respected industry professionals and SMEs.

    Mock FDA Audits

    Are you fully prepared for an inspection at your facility?

    Our team of experienced ex-FDA investigators offer comprehensive Mock FDA Audit services to help you prepare for an actual FDA inspection. Our team of experts will conduct a thorough inspection of your facility, review your documentation, and provide you with valuable feedback on areas that need improvement to ensure compliance with FDA regulations – both remotely and on-site.

    Learn More About Mock FDA Audits

    OnCall Image

    Recent Posts

    The Lachman Consultants Blog

    The latest on industry compliance, regulatory affairs, technical services, and a whole lot more.

    Get Ready for PDUFA Program Fee Invoices for 2027

    Today, the FDA has sent out a PDUFA Dear Colleague letter (here) askin...
    Read More

    Cosmetics Have Taken a Giant Leap Forward Since 2022!

    While cosmetics have been included in the Federal Food, Drug, and Cosm...
    Read More

    Preliminary Decision to Exclude Certain GLP-1 Drugs From the 503B Bulks List

    Today, the FDA published a Federal Register (FR) notice (here) announc...
    Read More

    FDA Proposes to Withdraw Approval of Tavneos NDA After New Information Comes to Light

    On April 29, 2026, the FDA published a notice in the Federal Registe...
    Read More
    Office of Compliance Issues 2025 Annual Report

    Office of Compliance Issues 2025 Annual Report

    This month, April 2026, the Center for Drugs Evaluation and Researchâ€...
    Read More

    Day Two Helpful Hints from the Generic Drugs Forum 2026

    The second day of the Generic Drugs Forum provided a significant amoun...
    Read More
    ADVANCE CONFIDENTLY
    Contact Us Today